With the aim of growing its neurodegenerative diseases business, Zhejiang Jingxin Pharmaceutical has reached an agreement to acquire up to 5% stake in Israeli-based Pharma Two B.
The Chinese company will pay a purchase consideration of $5m to the target company, as part of the transaction.
The target company develops treatment for Parkinson's disease and cancer, while the acquirer company is a Chinese pharmaceutical company.
Israeli biopharmaceutical company BioLineRx has completed the acquisition of Agalimmune and its technology platform, with the aim of enhancing its position in the immuno-oncology space.
The UK-based target company, which develops anti-cancer immunotherapy products, has received $6m in purchase consideration for the transaction, including $3m in cash and the remaining in the acquirer company’s shares.
The target company is also entitled for future development and commercial milestone-based payments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData